Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results

Hims & Hers Health (NYSE:HIMS) announced third-quarter 2026 financial results after market hours on Monday, November 9. The telehealth company reported revenue of $608.1 million, a 3.8% increase from the same quarter a year earlier, according to TradingView. That figure was in line with Wall Street estimates for the quarter, Yahoo Finance reported, but the company missed analysts' earnings-per-share expectations and its EBITDA guidance for the next quarter fell significantly short of consensus.

The company added 73,000 customers during the quarter, bringing its total to 2.58 million, TradingView said. Despite the customer growth, Hims & Hers narrowed its full-year sales outlook and cut its 2026 profit forecast as margins contracted, according to Reuters and The Wall Street Journal. Investor's Business Daily described the guidance as "light" and noted the stock took a dive on the news.

Analysts covering the company had generally reconfirmed their estimates over the prior 30 days, suggesting they expected the business to stay the course heading into earnings, TradingView reported. However, Hims & Hers has missed Wall Street's revenue estimates multiple times over the last two years. The market had been expecting revenue to grow 28.3% year on year this quarter, slowing from the 72.6% increase recorded in the same quarter last year.

Shares of Hims & Hers were down 7.9% over the month leading into the report, while the broader healthcare technology segment rose 3.2% on average, TradingView said. The stock headed into earnings with an average analyst price target of $29.23, below the then-current share price of $31.67. Peers GoodRx and Tandem Diabetes both traded higher after their recent results, up 13.8% and 19.1% respectively.

The company's investor relations release confirmed the results but did not provide additional commentary beyond the financial tables. Barron's had previewed the earnings with a note on what to expect, and TradingView's pre-earnings analysis highlighted the history of revenue misses. The narrowed outlook and margin pressure signal a more cautious trajectory for the remainder of 2026.